Cancer Stem Cell News Volume 11.14 | Apr 13 2022

    0
    116







    2022-04-13 | CSCN 11.14


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.14 – 13 April, 2022
    TOP STORY

    CHMP2A Regulates Tumor Sensitivity to Natural Killer Cell-Mediated Cytotoxicity

    Scientists used a “two cell type” whole genome CRISPR-Cas9 screening system to discover key regulators of tumor sensitivity and resistance to natural killer cell-mediated cytotoxicity in human glioblastoma stem cells.
    [Nature Communications]

    Full Article
    Scientific resources to support your hematopoiesis research. Learn More!
    PUBLICATIONSRanked by the impact factor of the journal

    Rab13 Sustains Breast Cancer Stem Cells by Supporting Tumor-Stroma Crosstalk

    Researchers reported that Rab13, a small GTPase, was highly expressed in breast CSCs. Rab13 depletion suppressed breast cancer cell stemness, tumorigenesis, and chemoresistance by reducing tumor-stroma crosstalk.
    [Cancer Research]

    Abstract

    Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma

    Scientists showed that circadian locomotor output cycles kaput (CLOCK) and its heterodimeric partner brain and muscle ARNT-like 1 in glioma stem cells drove immunosuppression in glioblastoma.
    [Cancer Immunology Research]

    Abstract

    Mesenchymal and Stem-Like Prostate Cancer Linked to Therapy-Induced Lineage Plasticity and Metastasis

    Researchers defined mesenchymal and stem-like prostate cancer, traced its origin to therapy-induced lineage plasticity, and revealed its sensitivity to HER2/3 inhibition.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Growth Factor Independence Underpins a Paroxysmal, Aggressive Wnt5aHigh/EphA2Low Phenotype in Glioblastoma Stem Cells, Conducive to Experimental Combinatorial Therapy

    Scientists assessed that a subset of glioblastoma multiforme stem-like cells from high-grade gliomas was self-sufficient in the activation of regulatory growth signaling.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    Sinomenine Hydrochloride Suppresses the Stemness of Breast Cancer Stem Cells by Inhibiting Wnt Signaling Pathway through Down-Regulation of WNT10B

    Investigators explored the effect of sinomenine hydrochloride (SH) on breast cancer stem cells (BCSCs) and its mechanism and observed that SH decreased the ratio of CD44+/CD24 BCSCs and the expression of BCSCs-related genes in MCF-7 and MDA-MB-231 cells.
    [Pharmacological Research]

    Full ArticleGraphical Abstract

    Phenotypic and Molecular States of IDH1 Mutation-Induced CD24-Positive Glioma Stem-Like Cells

    The authors demonstrated that induction of a CD24-positive population is one mechanism by which IDH-mutant tumors acquired stem-like properties.
    [Neoplasia]

    Full Article

    A Positive Feedback Loop: RAD18-YAP-TGF-β between Triple-Negative Breast Cancer and Macrophages Regulates Cancer Stemness and Progression

    TGF-β from tumor-associated macrophages activated RAD18 in triple-negative breast cancer to enhance tumor stemness, forming a positive feedback loop. Inhibition of YAP or TGF-β broke this loop and suppressed cancer stemness and proliferation.
    [Cell Death Discovery]

    Full Article

    ISL1 Promotes Human Glioblastoma-Derived Stem Cells Self-Renewal by Activation of SHH/GLI1 Function

    Researchers established patient derived glioblastoma stem cells (GSCs), determined CSC marker expression, and immunostained GSCs to assess cell viability and apoptosis.
    [Stem Cells and Development]

    Abstract

    Methionine Restriction Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Stem Cells by miR-320d/C-myc Axis

    The combined chemotherapy with methionine restriction could enhance the chemotherapeutic sensitivity of colorectal cancer stem cells by up-regulation of miR-320d to inhibit c-Myc expression.
    [Molecular and Cellular Biochemistry]

    Abstract

    Epithelial-Mesenchymal Transition and Cancer Stem Cells: A Route to Acquired Cisplatin Resistance through Epigenetics in HNSCC

    Investigators suggested that in the route to cisplatin chemoresistance, epigenetic modifications could be associated with epithelial-mesenchymal transition activation and cancer stem cell accumulation which originated more aggressive tumors.
    [Oral Diseases]

    Abstract
    Enter your best cell image by April 28 for a chance to win!
    REVIEWS

    Immune Evader Cancer Stem Cells Direct the Perspective Approaches to Cancer Immunotherapy

    The authors summarize the role of immune cells providing CSCs to evade tumor immunity, and then discuss the intrinsic mechanisms represented by CSCs to promote tumors’ resistance to immunotherapies.
    [Stem Cell Research & Therapy]

    Full Article
    INDUSTRY AND POLICY NEWS

    SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase I Study

    SELLAS Life Sciences Group, Inc. announced that the first acute myeloid leukemia patient has enrolled in the fifth dose level cohort, out of the expected six dose cohorts, in the ongoing Phase I dose-escalating clinical trial with SELLAS’ newly in-licensed GFH009 asset.
    [SELLAS Life Sciences Group, Inc.]

    Press Release

    BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

    BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced that the US FDA has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT, for the treatment of metastatic breast cancer.
    [BriaCell Therapeutics Corp.]

    Press Release

    FEATURED EVENT

    ESMO Breast Cancer

    May 3 – 5, 2022
    Berlin, Germany

    > See All Events

    JOB OPPORTUNITIES

    Scientific Director – Cancer Research

    Cyprus Cancer Research Institute – Nicosia, Cyprus

    Tenure-Track Associate Professor – Stem Cell Biology

    The University of Hong Kong – Hong Kong, China

    Postdoctoral Position – Tumor Heterogeneity

    Luxembourg Institute of Health – Strassen, Luxembourg

    Postdoctoral Scientist – Translational Oncogenomics Group

    CRUK Manchester Institute – Manchester, United Kingdom

    Principal Scientific Researcher – Cell and Tissue Genomics

    Genentech, Inc. – South San Francisco, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter